Spatial Approximations between Residues 6 and 12 in the Amino-terminal Region of Glucagon-like Peptide 1 and Its Receptor

A REGION CRITICAL FOR BIOLOGICAL ACTIVITY*

Received for publication, April 19, 2010, and in revised form, June 4, 2010. Published, JBC Papers in Press, June 7, 2010, DOI 10.1074/jbc.M110.135749

Quan Chen, Delia I. Pinon, Laurence J. Miller, and Maoqing Dong

From the Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona 85259

Understanding the molecular basis of natural ligand binding and activation of the glucagon-like peptide 1 (GLP1) receptor may facilitate the development of agonist drugs useful for the management of type 2 diabetes mellitus. We previously reported molecular approximations between carboxyl-terminal residues 24 and 35 within GLP1 and its receptor. In this work, we have focused on the amino-terminal region of GLP1, known to be critical for receptor activation. We developed two high-affinity, full agonist photolabile GLP1 probes having sites of covalent attachment in positions 6 and 12 of the 30-residue peptide (GLP1(7–36)). Both probes bound to the receptor specifically and covalently labeled single distinct sites. Chemical and protease cleavage of the labeled receptor identified the juxtamembrane region of its amino-terminal domain as the region of covalent attachment of the position 12 probe, whereas the region of labeling by the position 6 probe was localized to the first extracellular loop. Radiochemical sequencing identified receptor residue Tyr145, adjacent to the first transmembrane segment, as the site of labeling by the position 12 probe, and receptor residue Tyr205, within the first extracellular loop, as the site of labeling by the position 6 probe. These data provide support for a common mechanism for natural ligand binding and activation of family B G protein-coupled receptors. This region of interaction of peptide amino-terminal domains with the receptor may provide a pocket that can be targeted by small molecule agonists.

Glucagon-like peptide 1 (GLP1),2 secreted by the intestinal L cells in response to food ingestion, is a glucagonrelin hormone that possesses multiple physiological functions, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon secretion and gastric emptying, and reduction in food intake, augmenting insulin biosynthesis, restoring β-cell sensitivity to glucose, increasing β-cell proliferation, and reducing apoptosis (1, 2). Because of these multiple antidiabetic actions and its ability to lower body weight, GLP1 receptor agonists have attracted much interest as a treatment for type 2 diabetes (3).

The GLP1 receptor is a member of the family B G protein-coupled receptors (GPCRs) that includes many important drug targets such as receptors for glucagon, glucagon-like peptide 2, gastric inhibitory polypeptide, secretin, vasoactive intestinal polypeptide, corticotropin-releasing factor, parathyroid hormone and calcitonin (4). A signature structural feature of this family is a long and structurally complex extracellular amino-terminal domain containing six conserved cysteine residues that form disulfide bonds that contribute to the development of a highly folded structure (5–9). This domain has been suggested to be the predominant domain for natural ligand binding and this is a consistent theme throughout the family (10–16). Natural ligands for family B receptors are all moderately long peptides in excess of 25 residues that have diffuse pharmacophoric domains, contributing to the complexity of their flexible interactions with the receptor amino-terminal domain. Like natural ligands for other members in the family B GPCRs, the amino-terminal portion of GLP1 is critical for the receptor selectivity and activation, whereas the carboxyl-terminal portion is critical for high affinity ligand binding (17). A tethering mechanism involving two domains of binding, with the carboxyl-terminal region of the ligand binding to the receptor amino terminus, and the amino-terminal region of the ligand possibly interacting with the receptor body, has been proposed for activation of this family of receptors (18–20).

Recently, our understanding of the molecular basis of ligand binding of the family B GPCRs has been substantially advanced with the solution of the NMR and crystal structures of the amino-terminal domains of several members (7, 9, 21–25). Although these structures suggest similarity in structural motifs and ligand binding modes, there are inconsistencies in the absolute site of ligand binding and in the positioning of the ligand in these structures (26), suggesting some variation in binding mechanisms among this family of the receptors. Of note, these structures also included that of the amino-terminal domain of the GLP1 receptor bound with an antagonist (truncated exendin-4) and the natural GLP1 ligands (24, 25). Due to the lack of the experimental data on the intact receptor structures, our current understanding of the natural ligand binding and activation of this family of GPCRs is very limited. So far,
there is no consistent data for docking the amino-terminal region of the family B GPCR ligands and the orientation of the receptor amino-terminal domain relative to the core transmembrane domain (TM) is not clear.

We attempted to use the direct photoaffinity labeling approach to explore detailed spatial approximations between residues within GLP1 and those within the intact receptor. We have previously demonstrated that two carboxy-terminal GLP1 probes incorporating a photolabile p-benzoyl-l-phenylalanine (Bpa) in positions 24 and 35 labeled receptor residues Glu<sub>133</sub> and Glu<sub>125</sub>, respectively, both within the carboxy-terminal alanine (Bpa) in positions 24 and 35 labeled receptor residues Arg<sub>26,34</sub> GLP1(7–36) (Bpa<sub>12</sub> probe), was designed to incorporate a photolabile p-benzoyl-l-phenylalanine (Bpa) in positions 24 and 35 labeled receptor residues Glu<sub>133</sub> and Glu<sub>125</sub>, respectively, both within the carboxy-terminal region of the amino-terminal domain of the receptor (27). The amino-terminal region of family B GPCR ligands has been shown to be functionally important and to interact with the receptor body for several members (18–20). In this study, we focused on this region as possible sites of interaction with the body of the GLP1 receptor. Two photolabile probes were synthesized by incorporating a Bpa in positions 6 and 12 of the GLP1(7–36) peptide. Both probes bound specifically and satisfactorily to the GLP1 receptor and were full agonists. They were able to covalently label single and distinct residues within the receptor. Although position 12 probe continued to label the carboxy-terminal region of the amino-terminal domain of the GLP1 receptor, at residue Tyr<sup>145</sup>, position 6 probe indeed labeled a distinct region, at residue Tyr<sup>205</sup> within the first extracellular loop of the receptor. These findings add important constraints to the docking of GLP1 to its receptor and provide additional insights into the molecular mechanism proposed for ligand binding and activation of family B GPCRs.

**EXPERIMENTAL PROCEDURES**

**Materials**—Human GLP1(7–36)-amide (GLP1) was purchased from Bachem (Torrance, CA). The solid-phase oxidant, N-chlorobenzenesulfonamide (IDOBOEAD), cyanogen bromide (CNBr), 2-(2-nitrophenylsulfenyl)-3-methyl-3-bromoinodolene (Skatole), and N-maleimidobenzoyl-N-hydroxysulfosuccinimide ester were purchased from Pierce Chemical Co. Phenylmethanesulfonyl fluoride, 3-isobutyl-1-methylnithane, and N-(2-aminoethyl-1)-3-aminopropyl glass beads were from Sigma. ProSieve pre-stained protein standards were from Cambrex (Rochland, IN). Seebblue plus2 pre-stained and Multimark multicolored standards, and 10% NuPAGE gels were from Invitrogen. Endoproteinase Lys-C (Lys-C) was from Roche Applied Science. N-Glycosidase F (PNGase F) was from Proenzyme (San Leandro, CA). Soybean trypsin inhibitor (STI), Fetal Clone II, and tissue culture medium were from Invitrogen. Bovine serum albumin was from Serologicals (Norcross, GA). All other reagents were of analytical grade.

**Synthetic Peptides**—The photolabile GLP1 probe, [Bpa<sup>12</sup>, Arg<sup>26,34</sup>]GLP1(7–36) (Bpa<sub>12</sub> probe), was designed to incorporate a photolabile p-benzoyl-l-phenylalanine (Bpa) to replace a phenylalanine in position 12 within the amino-terminal region of the ligand. Another photolabile probe, [Bpa<sup>6</sup>,Arg<sup>26,34</sup>]GLP1(7–36) (Bpa<sub>6</sub> probe), was designed to incorporate a Bpa at the amino-terminal extension of the GLP1 ligand to minimize the negative functional impact on the critical residue, His<sup>7</sup>. Both probes contain a naturally occurring Tyr residue in position 19 as a site for radiodinated binding. Lysine residues in positions 26 and 34 were replaced by arginines to prevent Lys-C cleavage and this has previously been shown to be well tolerated (27, 28). They were synthesized by manual solid-phase techniques and purified by reversed-phase HPLC using procedures as previously described (29). Both probes and the natural GLP1 peptide were radioiodinated using a brief exposure for 15 s to the solid-phase oxidant, IODO-BEAD, as described previously (30). The radioiodinated peptides were purified by reversed-phase HPLC to yield specific radioactivities of ~2,000 Ci/mmol.

**Receptor Sources**—A Chinese hamster ovary cell line stably expressing the wild-type human GLP1 receptor was utilized as a source of receptor (CHO-GLP1R) (31). It was cultured in Ham’s F-12 medium supplemented with 5% Fetal Clone II on Falcon tissue culture plasticware in a 5% CO<sub>2</sub> environment at 37 °C. Cells were passaged approximately twice a week and lifted mechanically before use.

A new GLP1 receptor mutant was generated to introduce an additional site for CNBr cleavage, replacing residue Phe<sup>143</sup> with a methionine (F143M). Additionally, another new GLP1 receptor mutant representing alanine replacement of the critical residue of the Bpa<sub>12</sub> probe (Y145A) was prepared. Both mutants were prepared using the QuikChange Site-directed Mutagenesis kit from Stratagene (La Jolla, CA), with sequences verified by direct DNA sequencing. They were expressed transiently in COS-1 cells (American Type Culture Collection, Manassas, VA) after transfection using a modification of the DEAE-dextran method (32). Cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 5% Fetal Clone II in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C and harvested mechanically 72 h after transfection.

Plasma membranes were prepared from the above receptor-expressing cells using discontinuous sucrose gradient centrifugation (33). They were suspended in Krebs-Ringers/HEPES (KRH) medium (25 mm HEPES, pH 7.4, 104 mm NaCl, 5 mm KCl, 2 mm CaCl<sub>2</sub>, 1 mm KH<sub>2</sub>PO<sub>4</sub>, 1.2 mm MgSO<sub>4</sub>) containing 0.01% STI and 1 mm phenylmethysulfonyl fluoride and stored at ~80 °C until use.

**Ligand Binding**—The photolabile Bpa<sup>6</sup> and Bpa<sub>12</sub> probes were characterized to access their ability to bind receptor-bearing CHO-GLP1R cells using conditions that have been previously established (31). In brief, ~200,000 CHO-GLP1R cells per well in 24-well plates were incubated with a constant amount of the radioligand, 125I-GLP1 (5–10 pm), in the presence of increasing concentrations of the nonradioabeled Bpa<sup>6</sup> or Bpa<sub>12</sub> or control GLP1 (0 to 1 μM) in KRH medium containing 0.01% STI and 0.2% bovine serum albumin for 1 h at room temperature (reaction volume, 500 μl). After incubation, the cell-bound radioligand was separated from free radioligand by washing the cells twice with ice-cold KRH medium containing 0.1% STI and 0.2% bovine serum albumin. Cells were then lysed with 0.5 N NaOH and bound radioactivity was quantified using a γ-counter. Nonspecific binding was determined in the presence of 1 μM unlabeled GLP1 and represented less than 15% of total binding. The same assay was also utilized to characterize the binding activity of COS-1 cells transiently expressing the F143M and Y145A GLP1 receptor mutants. Data were analyzed...
and plotted using the nonlinear regression analysis routine for radioligand binding in the Prism program version 3.02 package (GraphPad Software, San Diego, CA) and are reported as the mean ± S.E. of duplicate determinations from a minimum of three independent experiments. Binding kinetics was determined by analysis with the LIGAND program of Munson and Rodbard (34).

**Biological Activity Assay**—The biological activities of the Bpa⁶ and Bpa¹² probes to stimulate CHO-GLP1R cells were assessed by measuring cAMP responses in these cells. Approximately 8,000 cells per well were grown in 96-well plates for 48 h. On the day of assay, cells were washed twice with phosphate-buffered saline and stimulated for 30 min at 37 °C with increasing concentrations of the Bpa⁶ or Bpa¹² probe or control GLP1 (0 to 1 μM) in KRH medium containing 0.01% STI, 0.2% bovine serum albumin, 0.1% bacitracin, and 1 mM 3-isobutyl-1-methylxanthine. Reactions were terminated by removing the medium and lysis in ice-cold 6% perchloric acid for 15 min with vigorous shaking. Lysates were adjusted to pH 6 with 30% KHCO₃ and the cAMP levels were assayed in a 384-well white Optiplate using a LANCE kit from PerkinElmer per the manufacturer’s instructions. The assay was performed in duplicate and repeated in at least three independent experiments. This assay was also used for characterization of the F143M and Y145A GLP1 receptor mutants expressed in COS-1 cells.

**Photoaffinity Labeling**—Covalent labeling of the GLP1 receptor was performed using procedures described previously (35). In brief, enriched receptor-bearing GLP1R-CHO membranes (~50 μg) were incubated with ~0.1 nM ¹²⁵I-labeled Bpa⁶ or Bpa¹² probe in 500 μl of KRH medium containing 0.01% STI and 1 mM phenylmethylsulfonyl fluoride in the presence of increasing amounts of competing GLP1 (0 to 1 μM) in the dark for 1 h at room temperature. The reaction was then exposed to photolysis for 30 min at 4 °C using a Rayonet photochemical reactor (Southern New England Ultraviolet Co., Bradford, CT) equipped with 3500-Å lamps. The membranes were then washed twice with ice-cold KRH medium and solubilized in SDS sample buffer before being applied to 10% SDS-polyacrylamide gels. Labeled products were visualized by autoradiography and band densitometry was performed by NIH ImageJ software. The apparent molecular masses of the radioactive bands were determined by interpolation on a plot of the mobility of ProSieve protein markers versus the log values of their apparent masses.

**Peptide Mapping**—This required preparation of the affinity labeled GLP1 receptor in larger scale. For this, ~200 μg and 0.5 nM ¹²⁵I-labeled Bpa⁶ or Bpa¹² probes were used. After gel electrophoresis, labeled bands were excised, eluted, lyophilized, and ethanol-precipitated before being used for chemical and enzymatic cleavage. Deglycosylation of labeled GLP1 receptor was performed with PNGase F following the protocol described in the manual. CNBr and Lys-C were used to cleave the labeled GLP1 receptor or mutant using procedures described previously (35). Products of cleavage were separated on 10% BisTris NuPAGE gel using MES running buffer and labeled bands were detected by autoradiography. The apparent molecular weights of the radiolabeled receptor fragments were determined by interpolation on a plot of the mobility of SeeBlue plus2 prestained or Multimark multicolored standards versus the log values of their apparent masses.

**Radiochemical Sequencing**—This was used to identify the specific receptor residue that was covalently labeled by each of the photolabile GLP1 probes. For the Bpa¹² probe, the receptor fragment Leu¹⁴⁴–Met²⁰⁴ resulting from CNBr cleavage of the F143M mutant receptor was purified to radioactive homogeneity and covalently coupled through receptor residue Cys²⁰⁵ to m-maleimidobenzoyl-N-succinimide-activated N-(2-aminoethyl-1)-3-aminopropyl glass beads. Manual cycles of Edman degradation were repeated, as has been reported previously (36), and the radioactivity released in each cycle was quantified using a γ-spectrometer.

For the Bpa⁶ probe, due to the fact that the photolabile Bpa residue was located in the first position of this peptide, it was required to prevent cleavage of the Bpa in the first cycle of radiochemical Edman degradation sequencing of the attached receptor fragment. Therefore, acetylation of the free amino group of the photolabile probe was performed with acetic anhydride after photoaffinity labeling of the receptor, but prior to CNBr cleavage, using the procedure we have previously described (19). The radioactive pure Tyr⁶¹–Met²⁰⁵ fragment resulting from CNBr cleavage of the acetylated wild-type receptor labeled with the Bpa⁶ probe was coupled through Cys²⁰⁵ to the glass beads for radiochemical sequencing. As control, this receptor fragment attached with the acetylated Bpa⁶ probe was again acetylated with acetic anhydride and used for radiochemical sequencing.

**Molecular Modeling**—Illustrative molecular models were prepared by homology. Separate models of the GLP1 peptide-occupied amino terminus and the helical bundle domain were prepared and oriented relative to each other. The amino terminus of the GLP1 receptor (residues 32–132) was prepared based on the crystal structure of the exendin-4(9–39)-bound GLP receptor (Protein Data Bank code 3c5t) (24). The helical bundle (residues 145–433) was based on the structure of rhodopsin (Protein Data Bank code 2z73) (37).

**RESULTS**

**Probe Characterization**—Both the Bpa⁶ and Bpa¹² GLP1 probes were synthesized and purified to purity >99%, with their identities verified by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. They bound to the GLP1 receptor specifically and saturably (GLP1, Kᵢ = 0.7 ± 0.1 nM; Bpa⁶ probe, Kᵢ = 11.2 ± 2.1 nM; Bpa¹² probe, Kᵢ = 1.2 ± 0.1 nM), and both were full agonists, stimulating maximal levels of cAMP in the CHO-GLP1R cells that were similar to that stimulated by natural GLP1, although they differed in potencies (GLP1, EC₅₀ = 19 ± 1 pM; Bpa⁶ probe, EC₅₀ = 738 ± 110 pM; Bpa¹² probe, EC₅₀ = 32 ± 7 pM). The binding affinity and potency for stimulating cAMP of the Bpa¹² probe were similar to that of natural GLP1, whereas those for the Bpa⁶ probe were lower (Fig. 1).

**Photoaffinity Labeling of the GLP1 Receptor**—The Bpa⁶ and Bpa¹² probes were used in photoaffinity labeling studies. As shown in Fig. 2, each of them labeled the GLP1 receptor specifically and saturably, with labeling being inhibited by GLP1 in a concentration-dependent manner (Bpa⁶ probe, IC₅₀ = 24 ± 11
Bpa\textsuperscript{12} probe, IC\textsubscript{50} = 42 ± 9 nM). The receptor bands labeled with each of the probes migrated at molecular weight of approximately 66,000 and shifted to approximately 42,000 after deglycosylation with PNGase F, as expected for this receptor (27). No radioactive band was observed in affinity labeled membranes prepared from non-receptor-bearing CHO cells.

Identification of the Bpa\textsuperscript{12} Probe-labeled Receptor Site—Because CNBr quantitatively cleaves proteins at the carboxyl-terminal side of methionine residues, it was chosen to gain initial insights into the regions of labeling by the Bpa\textsuperscript{12} probe. The GLP1 receptor contains 10 methionine residues and CNBr cleavage would theoretically result in 11 receptor fragments ranging in molecular masses from under 1 to more than 21 kDa, with only one of these containing sites of glycosylation (Fig. 3). Fig. 3 shows that CNBr cleavage of the labeled GLP1 receptor yielded a band that migrated at molecular weight of approximately 50,000 and shifted to approximately 24,000 after deglycosylation with PNGase F. Considering the molecular mass of the attached Bpa\textsuperscript{12} probe (3,583 Da) and the glycosylated nature of the labeled band, the labeled receptor fragment could be limited to only one candidate. This was the fragment including the extracellular amino-terminal domain, the first and second transmembrane domains, and the first intracellular loop (Val\textsuperscript{18}–Met\textsuperscript{204} highlighted in black circles in Fig. 3).

Endoproteinase Lys-C, which cleaves a protein at the carboxy-terminal side of lysine residues, was used to further narrow down the domain of labeling by the Bpa\textsuperscript{12} probe. As shown in Fig. 4, Lys-C cleavage of the labeled GLP1 receptor yielded a band migrating at molecular weight of approximately 11,000 that did not shift further after deglycosylation. There was only one candidate to represent this, i.e. the Arg\textsuperscript{131}–Lys\textsuperscript{197} fragment spanning the amino terminus, TM1, first intracellular loop, and TM2 (Fig. 4).

To further localize the site of labeling by the Bpa\textsuperscript{12} probe, a new receptor mutant, F143M, was prepared and transiently expressed in COS-1 cells. This mutant construct bound GLP1 (WT, \(K_i = 2.1 \pm 0.5\) nM; F143M, \(K_i = 1.4 \pm 0.5\) nM) and signaled similarly to the wild-type GLP1 receptor (EC\textsubscript{50} = 32 ± 13 pm; EC\textsubscript{50} = 47 ± 24 pm). It was efficiently and specifically labeled with the Bpa\textsuperscript{12} probe (data not shown). After CNBr cleavage, the \(M_c = 50,000\) band from cleavage of the wild-type receptor shifted to \(M_c = 11,000\) in the F143M mutant receptor, indicating that the site of labeling was within the segment between Leu\textsuperscript{148} and Met\textsuperscript{204} (Fig. 5). Considering the above identification by Lys-C cleavage, the site of labeling by the Bpa\textsuperscript{12} probe was between Leu\textsuperscript{148} and Lys\textsuperscript{197}, within the juxtamembrane region of the amino-terminal domain of the GLP1 receptor.

The specific site of labeling with the Bpa\textsuperscript{12} probe was identified by manual radioactive Edman degradation sequencing of the radiochemically pure CNBr fragment.
(Leu^{144}-Met^{204}) from the labeled F143M GLP1 receptor mutant. As shown in Fig. 6, a peak in eluted radioactivity appeared in cycle 2, corresponding to the covalent labeling of receptor residue Tyr^{145} in the juxtamembrane region of the amino-terminal domain of the GLP1 receptor.

Identification of the Bpa6 Probe-labeled Receptor Site—To gain an initial insight into the domain of labeling by the Bpa6 probe, we also used CNBr to cleave the labeled wild-type GLP1 receptor. As shown in Fig. 7, CNBr cleavage of the labeled GLP1 receptor yielded a band migrating at an approximate \( M_r = 6,000 \) that did not further shift after PNGase F treatment. Considering the molecular mass of the attached Bpa6 probe (3,729 Da) and the non-glycosylated nature of the labeled fragment, two fragments were felt to be candidates. These represented the Tyr^{205}-Met^{233} fragment containing the ECL1 and the Asp^{372}-Met^{397} fragment containing the ECL3 of the GLP1 receptor.

Further efforts were made to identify which of the above two candidate fragments contained the site of labeling for the Bpa6 probe. Interestingly, the Tyr^{205}-Met^{233} fragment had a Trp residue at position 214, whereas the Asp^{372}-Met^{397} fragment contained no Trp residues. Therefore, Skatole, which cleaves a protein at the carboxyl-terminal end of tryptophan residues, was used to further cleave the CNBr fragment labeled with the Bpa6 probe. As shown in Fig. 8, the \( M_r = 6,500 \) CNBr fragment shifted to \( M_r = 4,500 \) after Skatole cleavage. This indicated that the fragment including the ECL1 contained the site of labeling for the Bpa6 probe, likely within the Tyr^{205}-Trp^{214} segment based on its migration. This was confirmed by CNBr cleavage of another M397L mutant receptor in which Met^{397} was mutated to a Leu (data not shown).

The identification of the specific site of labeling by the Bpa6 probe was achieved by sequencing the radiochemically pure Tyr^{205}-Met^{233} fragment from CNBr cleavage of the acetylated wild-type GLP1 receptor. As shown in Fig. 9, a peak in eluted radioactivity appeared in the first cycle of the Edman degradation sequencing, representing covalent labeling of the receptor Tyr^{205} residue with the Bpa6 probe within the ECL1 of the GLP1 receptor. In the control experiment, no radioactive peak was observed when radiochemical sequencing of the same receptor fragment acetylated with acetic anhydride (data not shown).

Functional Characterization of Receptor Site Mutants—The function of GLP1 receptors incorporating an alanine replacement for each site of photoaffinity labeling was studied. The Tyr^{145} residue of the GLP1 receptor labeled by the Bpa^{12} probe was mutated to an alanine, expressed transiently in COS-1 cells, and studied for impact on the binding and biological activity of GLP1. As shown in Fig. 10, mutation of this residue had no significant effects on the binding or biological effects of GLP1. Similarly, alanine replacement of the Tyr^{205} residue labeled by the Bpa^{6} probe did not result in significant changes in GLP1 binding affinity or biological activity (38).

Molecular Modeling—Fig. 11 illustrates the general feasibility of docking GLP1 to its receptor components, because meaningful molecular modeling of an intact receptor will require additional spatial constraints to orient the receptor amino ter-
minus relative to its core domain and to direct the interactions between what likely represents a flexible amino terminus of the peptide and the core domain of the receptor.

**DISCUSSION**

Family B GPCRs are an important family of potential drug targets that regulate a wide range of endocrine and neuroendocrine functions. Our current understanding of the molecular basis of ligand binding and activation of the GLP1 receptor and other members in this family remains a major obstacle for the further development of potent receptor ligands of pharmaceutical interests. Although with recent advancement in the solution of high-resolution structures of the predominant binding domain, the amino-terminal domain, of multiple members of this family, the mechanism of activation of this group of receptors is not yet clear due to the lack of structural information of the intact receptors. In this work, we used photoaffinity labeling to explore residue-residue approximations between the functionally critical amino-terminal region of GLP1 and its intact receptor as this region has previously been shown to interact with the body of several other family members (18–20, 39).

The design of photolabile GLP1 probes to incorporate a Bpa at the amino-terminal extension of the GLP1(7–36), in position 6. Indeed, this Bpa probe bound the GLP1 receptor specifically and saturably, although with affinity somewhat lower than that of natural GLP1. More importantly, this probe was a fully efficacious agonist with potency much higher than [Ala7]GLP1 (28). It is noteworthy that incorporation of the bulky, hydrophobic Bpa moiety at position 12 to replace a conserved phenylalanine was better tolerated than Ala replacement (28, 40), yielding a peptide probe that bound and signaled similarly to natural GLP1. This is important because it assures retaining the determinants of binding and activation intrinsic to the natural hormone.

The current report provided direct spatial approximation between residue 12 at the amino-terminal region of GLP1 and receptor Tyr145 residue, at the carboxyl-terminal end of the amino terminus, just above the top of the first transmembrane domain (TM1). Of note, this residue was in the same region as the receptor residues Glu125 and Glu133 that were labeled by carboxyl-terminal Bpa35 and Bpa24 GLP1 probes, respectively (27). This Tyr145 residue is adjacent to a functionally important residue, Thr149 of the GLP1 receptor, in which a T149M mutation was found in a type 2 diabetes patient that exhibited impairment of insulin secretion, insulin sensitivity, and glucose tolerance (41). This mutant has been shown to exhibit reduced binding affinity and biological activity efficacy for GLP1 in COS-7 cells (42). The site of labeling of the Bpa12 GLP1 probe
within its receptor was within the analogous region of the calcitonin receptor where a mid-region position 16 probe labeled (43) and of the PTH1 receptor where a carboxyl-terminal position 33 (44) and multiple mid-region (positions 11, 13, 15, 18, and 21) PTH probes labeled (45, 46). This is also the analogous region of the VPAC1 receptor labeled by amino-terminal positions 0 and 6, and carboxyl-terminal positions 22, 24, and 28 vasoactive intestinal polypeptide probes (47–49). Interestingly, this juxtamembranous region of the amino terminus of the calcitonin receptor has been recently shown to play a critical role in small-molecule agonist action (50).

The current report also provides direct spatial approximation between the amino terminus of GLP1 and receptor residue Tyr205, a residue within the ECL1 of the GLP1 receptor. Mutagenesis has identified multiple important residues within this region for GLP1 binding that included most of the charged residues including Lys197, Asp198, Lys202, Asp215, and Arg227 (51, 52). Interestingly, double alanine scanning of this region revealed that mutation of Met204–Tyr205 to alanines resulted in a 90-fold decrease in GLP1 binding and essentially abolished the biological activity, likely due to a loss in hydrophobicity in this region (38). In that work, the authors predicted the Met204–Tyr205 residues were important for binding to GLP1 residues in the amino-terminal region. Our current work unambiguously established the spatial approximation between this Tyr205 residue and the amino terminus of the GLP1 peptide. The importance of the ECL1 in ligand binding has also been demonstrated for several other family B GPCRs by mutagenesis (32, 53, 54). Photoaffinity labeling has established this region as the domain of labeling of the PTH1 receptor for mid-region position 19 and carboxyl-terminal position 27 PTH probes (55, 56), and as that of the corticotropin-releasing factor 1 receptor for mid-region positions 17 and 22 urocortin probes (39).

Of note, alanine replacement of each of the residues labeled by the Bpa6 and Bpa12 probes (Tyr205 and Tyr145, respectively) within its receptor was within the analogous region of the calcitonin receptor where a mid-region position 16 probe labeled (43) and of the PTH1 receptor where a carboxyl-terminal position 33 (44) and multiple mid-region (positions 11, 13, 15, 18, and 21) PTH probes labeled (45, 46). This is also the analogous region of the VPAC1 receptor labeled by amino-terminal positions 0 and 6, and carboxyl-terminal positions 22, 24, and 28 vasoactive intestinal polypeptide probes (47–49). Interestingly, this juxtamembranous region of the amino terminus of the calcitonin receptor has been recently shown to play a critical role in small-molecule agonist action (50).

The current report also provides direct spatial approximation between the amino terminus of GLP1 and receptor residue Tyr205, a residue within the ECL1 of the GLP1 receptor. Mutagenesis has identified multiple important residues within this region for GLP1 binding that included most of the charged residues including Lys197, Asp198, Lys202, Asp215, and Arg227 (51, 52). Interestingly, double alanine scanning of this region revealed that mutation of Met204–Tyr205 to alanines resulted in a 90-fold decrease in GLP1 binding and essentially abolished the biological activity, likely due to a loss in hydrophobicity in this region (38). In that work, the authors predicted the Met204–Tyr205 residues were important for binding to GLP1 residues in the amino-terminal region. Our current work unambiguously established the spatial approximation between this Tyr205 residue and the amino terminus of the GLP1 peptide. The importance of the ECL1 in ligand binding has also been demonstrated for several other family B GPCRs by mutagenesis (32, 53, 54). Photoaffinity labeling has established this region as the domain of labeling of the PTH1 receptor for mid-region position 19 and carboxyl-terminal position 27 PTH probes (55, 56), and as that of the corticotropin-releasing factor 1 receptor for mid-region positions 17 and 22 urocortin probes (39).

Of note, alanine replacement of each of the residues labeled by the Bpa6 and Bpa12 probes (Tyr205 and Tyr145, respectively)
had no impact on the binding and biological activity of the natural ligand, GLP1. This phenomenon is actually the most common in this type of study. Photoaffinity labeling as applied in this work is used to identify spatial approximation between residues within a docked peptide ligand and its receptor, rather than defining interacting residues. These distances can be used as constraints for molecular modeling, due to the direct nature of the insight, but often do not represent functionally important interactions. Indeed, if residue-residue interactions were very important to function, the replacement of the natural residue with a photolabile residue would likely not be well tolerated and might have a more profound negative impact on binding or biological activity than what was observed here.

Our current identification of the spatial approximation between the amino terminus of GLP1 and the Tyr²⁰⁵ residue within the ECL1 of its receptor could provide a mechanism for activation of this receptor. Generally speaking, this is consistent with the common two-domain tethering mechanism for ago-
nist ligand binding proposed for the secretin, PTH, and calcitoning receptors (18–20). However, it should be noted that this proposed mechanism is considered a low-resolution model because multiple ligand-receptor contacts have been demonstrated within each of the two broadly defined interactions and these contacts differ from one receptor to another. For the secretin receptor, multiple residues within the mid-region and carboxy-terminal region have been demonstrated to dock within the amino-terminal domain and so far, only amino-terminal residues 1 and 5 have been shown to interact with the top of TM6 and ECL3 (19, 57). This is the analogous region of PTH1 (18, 58) and PTH2 (59) receptors labeled by the amino-terminal PTH probes. Recently, the amino terminus of PTH has also been shown to additionally interact with a residue within TM5 of its receptor using a disulfide trapping approach (60). In addition, mid-region position 19 and carboxy-terminal position 27 residues of PTH have also been shown to interact with the body of its receptor, with distinct residues in TM2 and ECL1, respectively (55, 56). For the corticotropin-releasing factor 1 receptor, amino-terminal positions 0 and 12 of urocortin have been shown to interact with ECL2, with midregion positions 17 and 22 of the ligand interacting with ECL1 (39). The VPAC1 receptor may use a different mechanism because as described above, both amino- and carboxy-terminal residues of vasoactive intestinal polypeptide have been shown to interact with the juxtamembranous region of the receptor (47–49). For the GLP1 receptor in this work, the amino terminus of GLP1 was demonstrated to interact with ECL1 of its receptor, a distinct region from those of other family B GPCRs. It should be interesting to test a broader spectrum of residues in different regions of GLP1 for possible interactions with other parts of the receptor body that will ultimately help to orient the receptor amino terminus, the predominant ligand binding domain, relative to the receptor core domain.

Unfortunately, the existing crystal structures of GLP1 or the GLP analogue bound to portions of the amino terminus of the GLP1 receptor (24, 25) do not include the regions identified in the current report. These structures were most informative of the interactions between the carboxy-terminal region of GLP1

![FIGURE 10. Characterization of the Y145A GLP1 receptor mutant. Shown in the left panel are competition-binding curves of increasing concentrations of GLP1 to displace the binding of radioligand 125I-GLP1 to COS-1 cells expressing wild-type (WT) and Y145A GLP1 receptors. Values illustrated represent saturable binding as percentages of maximal binding observed in the absence of the competing peptide. They are expressed as the mean ± S.E. of duplicate values from a minimum of three independent experiments. Shown in the right panel are intracellular cAMP responses to increasing concentrations of GLP1 in these cells. Data points represent the mean ± S.E. of three independent experiments performed in duplicate, normalized relative to the maximal response to GLP1.](image)

![FIGURE 11. Graphic illustration of the feasibility of docking GLP1 with the two major regions of the GLP1 receptor, the amino terminus and the helical bundle core domain. Shown are homology models of docking GLP1 with the amino terminus (orange) and the helical bundle core domain (gray) of the GLP1 receptor. It should be noted that the region between residues 133 and 144 linking the amino terminus with the top of transmembrane segment was not included in this illustration because its structure was not well defined in the published crystal structures. The GLP1 peptide is colored blue to red from its amino terminus to its carboxyl terminus. Residues within GLP1 representing positions of photolabile moieties for affinity labeling (His7, Phe12, Ala24, and Gly35) are shown in green. The receptor residue, Glu125, labeled by the probe at position 35 was colored in cyan, whereas the receptor residue labeled by the probe at position 24, Glu133, is not illustrated, because it is within an unconstrained region of the receptor. The two receptor residues photoaffinity labeled by the probes at positions 12 and 6 in the current study, Tyr145 and Tyr205, respectively, are highlighted by Corey-Pauling-Koltun representation. The green-dotted lines link the sites of photoactivation with sites of covalent labeling.](image)
with the receptor. The current report extends these insights to the docking of the amino terminus of the peptide. Although we established spatial approximations for two positions within this region of GLP1, we believe that these constraints are not yet adequate to propose a meaningful intact receptor model. Of note, an intact GLP1 receptor model has recently been proposed for tentative docking of both peptide and small molecule ligands based on very limited, indirect mutagenesis data (61); however, it does not accommodate the experimentally derived spatial approximation constraints determined in the current work. In that model (61), positions 6 and 12 of GLP1 were quite distant from their labeling sites, Tyr105 and Tyr145, 12.33 and 16.79 Å, respectively. This further indicates the need of a large amount of experimental spatial residue-residue constraints to build a credible model for flexible GLP1 docking to its receptor.

To date, we have identified four pairs of spatial approximation constraints between residues within the amino- and carboxyl-terminal regions of GLP1 and its receptor. Although these constraints provide important insights into our understanding of the molecular basis of ligand binding and activation of this important receptor and other family B GPCRs, currently, there are not adequate data to build a meaningful ligand-bound intact GLP1 receptor model.

Acknowledgments—We thank Mary L. Augustine and Alicia M. Ska-lecka Ball for technical assistance. We also thank Dr. Yuedong Yang, who used the SPARKS-X server at Indiana University Purdue University, Indianapolis, to prepare an illustrative molecular model.

REFERENCES

1. Baggio, L. L., and Drucker, D. J. (2007) Gastroenterology 132, 2131–2157
2. Drucker, D. J. (2005) Nat. Clin. Pract. Endocrinol. Metab. 1, 22–31
3. Estall, J. L., and Drucker, D. J. (2006) Cur. Pharm. Des. 12, 1731–1750
4. Mayo, K. E., Miller, L. J., Bataille, S., Sexton, P. M., Gao, F., and Miller, L. J. (2008) J. Biol. Chem. 283, 11340–11347
5. Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., and Reedtz-Runge, S. (2010) J. Biol. Chem. 285, 723–730
6. Partther, C., Reedtz-Runge, S., Rudolph, R., and Stubbs, M. T. (2009) Trends Biochem. Sci. 34, 303–310
7. Chen, Q., Pinon, D. I., Miller, L. J., and Dong, M. (2009) J. Biol. Chem. 284, 34135–34144
8. Dong, M., Gardella, T. J., Madsen, K., Lau, J., and Rudolph, R. (2008) J. Biol. Chem. 283, 12900–12912
9. Powers, S. P., Pinon, D. I., and Miller, L. J. (1988) Int. J. Pept. Protein Res. 31, 429–434
10. Ulrich, C. D., 2nd, Pinon, D. I., Hadac, E. M., Holicky, E. L., Chang-Miller, A., Gates, L. K., and Miller, L. J. (1993) Gastroenterology 105, 1534–1543
11. Dong, M., Gao, F., Pinon, D. I., and Miller, L. J. (2008) Mol. Endocrinol. 22, 1489–1499
12. Holtmann, M. H., Chang-Miller, A., Dota, V., and Miller, L. J. (1996) J. Biol. Chem. 271, 14941–14949
13. Hadac, E. M., Ghanekar, D. V., Holicky, E. L., Pinon, D. I., Dougherty, R. W., and Miller, L. J. (1999) J. Biol. Chem. 274, 903–909
14. Li, Z., Hadac, E. M., Henne, R. M., Patel, S. A., Lybrand, T. P., and Miller, L. J. (1997) J. Biol. Chem. 272, 24393–24401
15. Murakami, M., and Koyama, T. (2008) Nature 453, 363–367
16. Lopez de Maturana, R., Trecce-Birch, J., Abidi, F., Findlay, J. B., and Donnelly, D. (2004) Protein Pept. Lett. 11, 15–22
17. Kraeke, O., Hohan, B., Berger, H., Escher, E., Bienert, M., and Beyer, M. (2005) Biochemistry 44, 15569–15577
18. Gallwitz, B., Witz, M., Paetzold, G., Morys-Wortmann, C., Zimmermann, B., Eckart, K., Fölsch, U. R., and Schmidt, W. E. (1994) Eur. J. Biochem. 225, 1151–1156
19. Tokuyama, Y., Matsui, K., Egashira, T., Nozaki, O., Ishizuka, T., and Kanatsu, K. (2004) Diabetes Res. Clin. Pract. 66, 63–69
20. Beinborn, M., Worrall, C. I., McBride, E. W., and Kopin, A. S. (2005) Regul. Pept. 130, 1–6
21. Dong, M., Pinon, D. I., Cox, R. F., and Miller, L. J. (2004) J. Biol. Chem. 279, 1167–1175
22. Gensler, R. C., Gardella, T. J., and Jüppner, H. (2001) J. Biol. Chem. 276, 28650–28658
23. Zhou, A. T., Bessalle, R., Bisello, A., Nakamoto, C., Rosenblatt, M., Suva, L. J., and Chorev, M. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 3646–3649
24. Wittelsberger, A., Corich, M., Thomas, B. E., Lee, B. K., Barazza, A., Czodrowski, P., Mierek, D. F., Chorev, M., and Rosenblatt, M. (2006) Biochemistry 45, 2027–2034
25. Cauraudo, E. B., Cauraudo, E. A., Pinon, D. I., Miller, L. J., and Chorev, M. (2008) Mol. Endocrinol. 22, 147–155
26. Cauraudo, E., Pinon, D. I., Nicole, P., Cauraudo, A., and Miera, A. (2008) J. Mol. Neurosci. 36, 245–248
27. Tan, Y. V., Couvineau, A., Murail, S., Cauraudo, E., Neumann, J. M., Laca-
Molecular Basis of GLP1 Binding

père, J. J., and Laburthe, M. (2006) J. Biol. Chem. 281, 12792–12798
50. Dong, M., Cox, R. F., and Miller, L. J. (2009) J. Biol. Chem. 284, 21839–21847
51. López de Maturana, R., and Donnelly, D. (2002) FEBS Lett. 530, 244–248
52. Xiao, Q., Jeng, W., and Wheeler, M. B. (2000) J. Mol. Endocrinol. 25, 321–335
53. Piserchio, A., Bisello, A., Rosenblatt, M., Chorev, M., and Mierke, D. F. (2000) Biochemistry 39, 8153–8160
54. Du, K., Nicole, P., Couvineau, A., and Laburthe, M. (1997) Biochem. Biophys. Res. Commun. 230, 289–292
55. Gensure, R. C., Shimizu, N., Tsang, J., and Gardella, T. J. (2003) Mol. Endocrinol. 17, 2647–2658
56. Greenberg, Z., Bisello, A., Mierke, D. F., Rosenblatt, M., and Chorev, M. (2000) Biochemistry 39, 8142–8152
57. Dong, M., Lam, P. C., Pinon, D. I., Sexton, P. M., Abagyan, R., and Miller, L. J. (2008) Mol. Pharmacol. 74, 413–422
58. Behar, V., Bisello, A., Bitan, G., Rosenblatt, M., and Chorev, M. (2000) J. Biol. Chem. 275, 9–17
59. Behar, V., Bisello, A., Rosenblatt, M., and Chorev, M. (1999) Endocrinology 140, 4251–4261
60. Monaghan, P., Thomas, B. E., Woznica, I., Wittelsberger, A., Mierke, D. F., and Rosenblatt, M. (2008) Biochemistry 47, 5889–5895
61. Lin, F., and Wang, R. (2009) J. Mol. Model. 15, 53–65